In 2016, there were 16 listed companies with A net profit of more than 1 billion yuan in 2016, A share of a-shares and Hong Kong stocks. As the most profitable business, the companies' spending money is worth discussing. Purchase industry statistics found that affected by the factors such as marketing fee increase, the company's sales costs have continued to increase, there are six companies rose by more than 20%, one of the highest cost is 6.85 billion yuan for the step length of pharmacy. At the same time, under the trend of independent innovation, its r&d also generally have larger growth: eight firms r&d spending rose by more than 20%, of which six for the chemical medicine, hengrui pharmaceutical to invest 1.184 billion yuan in the top spot. 

 

Note: data specification 

 

This data is based on the financial results of a-share listed pharmaceutical companies, which are classified pharmaceutical manufacturing sector by the tongda letter. 

 

There may be omissions in some companies. If there are any data errors, please correct them. 

 

This data is for reference only. 

 

The 10 companies sold over 1 billion yuan 

 

According to incomplete statistics, more than 40 of the 183 a-share listed pharmaceutical companies are selling more than 1 billion yuan. Specific to 16 net profit more than 1 billion a-share listed companies, there are 10 companies selling cost over 1 billion yuan, step length pharmaceutical top spot with 6.85 billion yuan hengrui pharmaceutical followed by 4.352 billion yuan, in addition, baiyun mountain, fosun medicine, east China pharmaceutical, China resources keep the cost of sales are more than 3 billion yuan. 

 

It is worth mentioning that step drug because of its highest cost of sales, operating income proportion of biggest raise eyebrows at the same time, their sales ability is also amazing. According to the annual report, the company has 2,877 salespeople, while total sales of 12321 million yuan, or about 4.28 million yuan per sales person. 

 

Net profit exceeding 1 billion pharmaceutical enterprises (RMB 100 million) 

 

 

The 12 companies have r&d investment of up to 100 million yuan 

 

The r&d investment represents the innovation strength of the enterprise. Can be seen from the annual report data, with the domestic pharmaceutical industry gradually from the "sales" to "development drive", pharmaceutical companies are getting more and more willing to part with or use in research and development investment, relative, these corporate earnings growth are also considerable. 

 

Good performance is where the drug companies spend their money on research and development. Of the 16 companies with A net profit of more than 1 billion yuan, 12 have r&d investment of up to 100 million yuan. With an increase of 32.82 percent from the same period of last year, the company accounted for 10.68 percent of the total revenue, and the industry is the leading innovator of innovation. Fosun pharmaceuticals, which has a 7.60 per cent increase in research and development, followed the company with rmb11.06 billion in research and development, a year-on-year increase of 33.23%. 

 

It is worth noting that eight of the 16 pharmaceutical companies have spent more than 20 per cent year-on-year growth in r&d in 2016. Besides hengrui pharmaceutical and fosun medicine, sig pharmaceutical rose 61.79%, significantly step pharmaceutical, er kang pharmaceutical, new and into, Andy Sue, east China research and development of medicine are overweight. 

 

The net profit of 2016 was over 1 billion yuan ($1 billion).